GNA Biosolutions is a private molecular diagnostics company located in Germany. Our proprietary technology, Pulse Controlled Amplification (PCA), offers a novel, ultrafast, and cost-effective molecular diagnostic platform that captures and amplifies nucleic acids from complex clinical samples. PCA assays are being developed for a number of therapeutic areas, including infectious diseases and biothreats. Nucleic acid amplification is a fundamental process in molecular biology, with a multitude of applications. In collaboration with our partners around the world, our PCA technology is taking molecular testing to places it’s never been able to go before. Our vision is to bring the power of molecular testing, from sample to answer, to everyone, everywhere. For more information, please visit www.gna-bio.com
Location: Germany, Bavaria, Planegg
Employees: 11-50
Total raised: $20.15M
Founded date: 2010
Investors 5
| Date | Name | Website |
| - | OCCIDENT | occident.g... |
| - | Matterwave... | matterwave... |
| - | b2venture | b2venture.... |
| - | Unternehme... | uvcpartner... |
| - | SHS Gesell... | shs-capita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.09.2019 | Series C | $13.5M | - |
| 02.07.2015 | Series B | $6.65M | - |
Mentions in press and media 8
| Date | Title | Description |
| 10.03.2022 | GNA Surpasses $1 Billion in Secured Grants and Funding for Clean Transportation Clients | SANTA MONICA, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Gladstein, Neandross & Associates (GNA) announced today that the sum of public agency grants and funding it has secured on behalf of clients has surpassed $1 billion, representing... |
| 03.09.2019 | Daily funding roundup - September 3rd, 2019 | Culture Amp raised $82M; Elliptic closed $23M; GNA Biosolutions landed $13.5M; Parkable: Parkable is a sharing economy platform for car parking that allows companies and individuals to rent out their empty parking bays. Parkable has raised ... |
| 02.09.2019 | GNA Biosolutions Raises $13.5M in Series C Financing | GNA Biosolutions GmbH, a Munich, Germany-based molecular diagnostics company based in Germany, closed a $13.5M round of financing. Backers included new investors GreyBird Ventures, Occident, and Wachtumsfonds Bayern, and existing investors ... |
| 14.08.2019 | Daily funding roundup - August 14th, 2019 | Systum raised $10.7M; Flatfair closed $11M; GNA Biosolutions landed $13.5M Systum: Systum is a provider of a cloud-based, digital operating platform for small to medium-sized businesses. Systum has raised $10.7 million led by Octopus Ventur... |
| 13.08.2019 | Daily funding roundup - August 13th, 2019 | Baze raised $6M; Rimeto closed $10M; GNA landed $13.5M; OpenSpace secured $14M Baze: Baze has developed the first personalized nutrient supplement service. Baze has raised $6 million in Series A funding led by Nature’s Way. Read more Rimeto... |
| 12.08.2019 | GNA Biosolutions raises $13.5M for its first point-of-care molecular diagnostic W h i t e p a p e r Weighing the Costs: | GNA Biosolutions raised $13.5 million to support its point-of-care molecular diagnostics platform designed to quickly examine samples taken from whole blood, sputum and nasal swabs. Sponsored by Agilent Technologies How would you like to wi... |
| 12.08.2019 | GNA Biosolutions raises $13.5M for its first point-of-care molecular diagnostic | GNA Biosolutions raised $13.5 million to support its point-of-care molecular diagnostics platform designed to quickly examine samples taken from whole blood, sputum and nasal swabs. The Munich-based company’s series C round was backed by a ... |
| 02.07.2015 | GNA Biosolutions Raises €6M in Series B Financing | GNA Biosolutions GmbH (GNA), a Munich, Germany-based manufacturer of ultrafast pathogen diagnostic instruments, raised €6m in Series B financing round. The round was led by Robert Bosch Venture Capital (RBVC), with participation from SHS Ge... |